DKSH has signed a strategic partnership with Polpharma, a leading drug manufacturer in modern drugs, substances, and innovative solutions. DKSH willprovide comprehensive services for Polpharma’s wide portfolio of products in Vietnam.
Ho Chi Minh City, December 18, 2023 – DKSH’s Business Unit Healthcare, a leading Market Expansion Services provider in Asia and beyond, has successfully partnered with Polpharma to bring a wide range of products focusing on cardiology, gastroenterology, neurology, pulmonary, anti-infectives, dermatology, and ophthalmology into Vietnam. This partnership with Polpharma is one of the eight key strategic new partnerships that DKSH’s Business Unit Healthcare has entered this year in Vietnam to strengthen its position as the strategic healthcare solutions partner while providing healthcare for all.
Polpharma, the leader of the Polish pharmaceutical market and one of the leading drug manufacturers in the region of Central and Eastern Europe, is dedicated to producing medications in several domains such as anti-infectives, pain management, and cardiology. Polpharma’s success is driven by the purpose of helping people live healthy lives in a healthy world. This commitment isalso strengthened by the company’s affiliation with strong international partners such as DKSH. With DKSH’s broad industry expertise across 37 markets, together with deep local insights and an extensive partner network, Polpharma’s products will be made available to a wider population base in the Vietnamese market. The products will be distributed by local distributors.
Bernardo Reiner, Head of B2B Polpharma and General Manager of Farmaprojects stated: “We believe that DKSH’s strong capabilities and in-depth local understanding will help us achieve our business growth goals as we contribute to the industry development in potential markets like Vietnam. Together with DKSH, we will continue to help ensure healthy and long life for Vietnamese patients.”
Phillip Wray, General Director, DKSH Pharma Vietnam, shared: “As a strategic healthcare solutions partner across Asia and beyond, we utilize our world-class services and local insights to drive success for Polpharma. This collaboration aims to provide access to European-quality products from Polpharma as we continue to enrich people’s lives in Vietnam.”
About Polpharma
Polpharma Group: A leading regional (CEE and CIS) manufacturer of pharmaceuticals. Actively operating in the markets of Central and Eastern Europe, the Caucasus and Central Asia. For over 80 years, trusted by patients, healthcare professionals and business partners alike, offering modern medicines, substances and innovative solutions for patients and business partners from all over the world. 400 million medicines packages are made in our factories every year and commercialized directly or through a network of partners in more than 40 geographies globally. Covering the entire pharmaceutical value chain, Polpharma is open for partnerships along the entire value chain. With around more than 7,000 dedicated employees, Polpharma generates net revenues of more than EUR 1.1bn annually.
Our mission is to help people live a healthy life in a healthy world. Thanks to a wide portfolio of products from many therapeutic groups, we can support patients in the treatment and prevention of the many common diseases. We specialize in cardiology, neurology, ophthalmology, pulmonology, and gastroenterology. We operate in accordance with the idea of sustainable development, implementing our goals while respecting social and environmental aspects and the highest ethical standards.
About DKSH
DKSH’s purpose is to enrich people’s lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution, and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 37 markets with 32,600 specialists, generating net sales of CHF 11.3 billion in 2022. The DKSH Business Unit Healthcare is a trusted healthcare solutions partner across Asia and beyond. With around 7,990 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2022. www.dksh.com/hec